ReviewFrontiers in oncology2026
Artificial intelligence in prostate biopsy: diagnostic applications, risk stratification, and precision oncology.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate biopsy remains the cornerstone for the diagnosis, risk stratification, and management of prostate cancer. However, biopsy interpretation is challenged by sampling limitations, tumor heterogeneity, and interobserver variability in Gleason grading. Recent advances in digital pathology and artificial intelligence (AI) have created new opportunities to improve diagnostic accuracy, reproducibility, and clinical decision-making. This narrative mini-review summarizes current evidence regarding AI applications in prostate biopsy evaluation. Relevant studies published between 2015 and 2026 were reviewed, focusing on AI-assisted cancer detection, automated Gleason grading, quantitative pathology, prognostic assessment, and multimodal approaches integrating histopathological, molecular, and clinical data. AI-based systems have demonstrated high accuracy in prostate cancer detection, Gleason pattern classification, and tumor burden assessment, with several studies showing strong concordance with expert genitourinary pathologists. These technologies have the potential to improve diagnostic consistency, enhance workflow efficiency, refine risk stratification, and support treatment planning. Emerging multimodal AI models integrating histopathological, genomic, imaging, and clinical information may further improve prognostic assessment and facilitate precision oncology approaches. However, challenges remain, including limited prospective validation, data heterogeneity, regulatory considerations, model interpretability, and integration into routine clinical workflows. AI is emerging as a valuable adjunct in prostate biopsy evaluation, with the potential to enhance diagnostic precision, grading reproducibility, and personalized patient management. Continued multicenter validation, development of explainable AI frameworks, and effective integration into multidisciplinary prostate cancer care pathways will be essential for successful clinical adoption and improved patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.